Pharma 4.0 through cross pollination between industry and academia

(25-03-2021) Takeda Lessines and Ghent University’s Innovation Cluster CESPE Enter into Pharmaceutical Manufacturing Innovation Partnership

Cross pollination between industry and academia

Takeda and Ghent University (UGent) are pleased to announce that Takeda’s Global Manufacturing Site at Lessines has officially joined the CESPE innovation cluster, a multi-partner innovation accelerator in the field of pharmaceutical engineering and manufacturing. This strategic partnership reflects both parties’ strong desire to further intensify their research and innovation efforts and to make optimal use of the cross pollination between industry and academia. Initially, this partnership will focus on optimising digitization in Pharma 4.0, pharmaceutical technology innovation, and optimising energy and material efficiency during production. Takeda Lessines - engineer.jpg

“As one of the global leaders in the production of plasma derivatives, Takeda continuously improves its manufacturing operations. To this end, the mutual sharing of knowledge with other companies and knowledge institutions like CESPE is key." Gert Verheyden, Head of Manufacturing Sciences at Takeda Lessines

Mutual sharing of knowledge is key

“As one of the global leaders in the production of plasma derivatives, Takeda continuously improves its manufacturing operations. To this end, the mutual sharing of knowledge with other companies and knowledge institutions like CESPE is key”, says Gert Verheyden, Head of Manufacturing Sciences at Takeda Lessines. “This allows Takeda Lessines to make a significant contribution to the training of tomorrow’s pharmaceutical engineers, both in existing and emerging education tracks, and also to increase the industrial relevance of possible innovation projects at the international level.”

“We are thrilled to collaborate with Takeda and to thus facilitate its strong desire to implementing innovative production processes of active pharmaceutical ingredients and finished pharmaceutical products. We are collaborating precompetitively with an industrial network to build a strong knowledge region enabling the local anchoring of talent and innovation." Professor Thomas De Beer, Director of CESPE

About Takeda

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit www.takeda.com.

About UGent-CESPE

Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific and industrial cooperation. The organization is committed to research and innovation with an annual research budget of more than € 600 million and more than 5,500 researchers active in a wide range of the life, physical and social sciences. UGent TechTransfer and the UGent Business Development Platforms, such as CESPE, support researchers in developing groundbreaking science to bring innovations to the market.

The Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Its ambition is to become the reference centre in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way.

For more information, visit www.cespe.be.

 

Media contact

Takeda

Stefaan Fiers, Head of Corporate Communication         

0476 76 90 77

CESPE

Wouter De Soete, Manager

0474 80 65 67

Takeda.PNG  UGEnt.PNG   CESPE.PNG